Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5198492
Max Phase: Preclinical
Molecular Formula: C66H80BF2N11O11S
Molecular Weight: 1284.31
Associated Items:
ID: ALA5198492
Max Phase: Preclinical
Molecular Formula: C66H80BF2N11O11S
Molecular Weight: 1284.31
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)CCN1CCC(Oc2ccccc2Cc2ccccc2)CC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)NCCC(=O)N[C@@H](CCCCNC(=O)COc1ccc(/C=C/C2=[N+]3C(=Cc4ccc(-c5cccs5)n4[B-]3(F)F)C=C2)cc1)C(N)=O
Standard InChI: InChI=1S/C66H80BF2N11O11S/c1-43(2)37-53(75-61(84)30-35-78-33-28-51(29-34-78)91-57-15-7-6-13-46(57)38-45-11-4-3-5-12-45)65(88)77-55(41-81)66(89)76-54(40-59(70)82)64(87)73-32-27-60(83)74-52(63(71)86)14-8-9-31-72-62(85)42-90-50-24-18-44(19-25-50)17-20-47-21-22-48-39-49-23-26-56(58-16-10-36-92-58)80(49)67(68,69)79(47)48/h3-7,10-13,15-26,36,39,43,51-55,81H,8-9,14,27-35,37-38,40-42H2,1-2H3,(H2,70,82)(H2,71,86)(H,72,85)(H,73,87)(H,74,83)(H,75,84)(H,76,89)(H,77,88)/b20-17+/t52-,53-,54-,55-/m0/s1
Standard InChI Key: RYAGYNMVSFCLCI-DWKZJMNWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1284.31 | Molecular Weight (Monoisotopic): 1283.5821 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kok ZY, Stoddart LA, Mistry SJ, Mocking TAM, Vischer HF, Leurs R, Hill SJ, Mistry SN, Kellam B.. (2022) Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor., 65 (12.0): [PMID:35734860] [10.1021/acs.jmedchem.2c00125] |
Source(1):